Related Experiment Videos
Interleukin-2 treatment in lymphoma: a phase II multicenter study
C Gisselbrecht1, D Maraninchi, J L Pico
1Institut d'hématologie, Hôpital Saint Louis, Paris, France.
Blood
|April 15, 1994
Summary
High-dose recombinant interleukin-2 (rIL-2) showed activity in some lymphoma subtypes, particularly aggressive non-Hodgkin's lymphomas and mycosis fungoides. However, significant toxicity limited treatment in many patients.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Lymphoma is a heterogeneous group of cancers with various histologic subtypes.
- Recombinant interleukin-2 (rIL-2) is an immunomodulatory cytokine with potential anti-cancer activity.
Purpose of the Study:
- To evaluate the efficacy of continuous infusion high-dose rIL-2 in heavily pretreated lymphoma patients.
- To assess response rates across different lymphoma histologic subtypes.
Main Methods:
- A phase II study involving 61 lymphoma patients.
- rIL-2 administered as continuous infusion at 20 x 10(6) IU/m2 over three cycles.
- Patients included low-grade NHL, aggressive NHL, Hodgkin's disease, and mycosis fungoides.
Main Results:
- One complete response (CR) in low-grade NHL; three CRs and two partial responses (PRs) in aggressive NHL.
- No response in Hodgkin's disease; one CR and four PRs in mycosis fungoides.
- Grade 4 toxicity occurred in 29 patients, leading to treatment cessation in 12.
Conclusions:
- Continuous infusion high-dose rIL-2 demonstrates differential activity in lymphoma subtypes.
- Aggressive NHL and mycosis fungoides showed promising responses, warranting further investigation.
- Toxicity is a significant concern requiring careful management.